Over the past 18 months, Disposable Eye Spear industry trends have been reshaped by a wave of consolidation and innovation. In Q1 2024, BVI Medical acquired Oasis Medical’s ophthalmic spear portfolio for an undisclosed sum, integrating ultra-fine PVA foam technology into its surgical kits and doubling U.S. outpatient share. Shortly after, Alcon and Foamtec Medical formed a strategic alliance to co-develop biodegradable spears with embedded micro-antimicrobial fibers, targeting ASCs seeking greener supply chains. Regulatory momentum also accelerated: the FDA’s March 2024 reclassification of single-use ophthalmic sponges to Class II with special controls shortened 510(k) clearance timelines to roughly 90 days, prompting four new entrants—VortexVision, AquaSpear, ClearSight Surgical, and NanoWipe—to launch lint-free, high-absorbency spears optimized for femto-cataract workflows. Consumer demand is shifting toward procedure-specific packs; hospitals now favor spears bundled with pre-loaded moxifloxacin inserts, a preference that lifted ASPs 8 % YoY. Finally, SightSaver closed a $22 M Series B in January 2024 to scale plasma-coated spears that reduce corneal staining, expanding its footprint across 40 EU ophthalmology clinics.
